vimarsana.com

Latest Breaking News On - Trivalve registry - Page 1 : vimarsana.com

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

May 21, 2021 Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR. On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche. All three are manufactured by Edwards Lifesciences: Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.